1) IDOVEN the Madrid-based European HealthTech startup that seeks to prevent world cardiac diseases, heart attacks and sudden cardiac death, has just raised €2 million at a pre-money valuation of €10 million.
The cardiology platform, that enables anyone to learn how their heart works and helps doctors around the world, has announced that it has received €2 million in Seed Funding from Accel Partners; Wayra, Telefónica's open innovation hub; world-class Top-level Business Angels and ENISA, bringing the company’s total funding up to more than €3 million, joining previous investors such as Iker Casillas.
2) Biomensio closed its funding round in record time! They raised 5M€ in under 2 days with Springvest finnish investment platform. That’s really impressive!
Biomensio is a Finnish biotech startup company, which was founded in 2015 as a spin-off of Siemens AG and the Technology Research Center VTT Oy. The company is developing next-generation mobile, multiplexing (simultaneous detection of multiple analytes) and rapid diagnostics for ever-growing field testing needs, outside of the laboratory environment.
3) We are also happy to announce that Hefring Marine has successfully closed a financing round led by the New Business Venture Fund, an Icelandic state-owned venture capital fund, with the participation of Innoport, the venture capital unit of the Schulte Group, and TechNexus, a U.S. based venture collaborative.
The Hefring Marine system provides vessel operators with an intelligent solution to improve situational awareness, safety, and efficiency on board. It analyzes real-time data from vessel operations to adapt and optimize speed, route and decisions while logging all trip data to improve tracking, monitoring and planning. The solution can help to improve on board welfare and safety and reduce power demand during vessel operation.
4) InvestHorizon‘s accelerated Swiss startup Calciscon AG raised CHF 2.5 M Series A to commercialize the T50 Test to drive more efficient therapies for renal patients.
Calciscon announced the closing for its Series A financing, led by Yellowstone Holding, for CHF 2.5M. The proceeds of the financing enable the company to accelerate the introduction of its T50 test in routine clinical use in Europe and prepare for US launch. The T50 test is a modern, first-of-its-kind blood test, which measures calcification propensity. This information helps doctors to better guide therapies of kidney disease patients.
Read here the interview with founder PD Dr. Andreas Pasch.
Launched in June 2019, the InvestHorizon Accelerator has already supported 450 SMEs. The programme is financed by the European Commission, in association with Eureka, to facilitate series A funding for selected deep tech companies boosting their investment readiness and investor relations. The sample of the first 131 companies raised already 53+ million EUR equity funding. More details are available here.
InvestHorizon is a program financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor relations. The program is run by a consortium coordinated by Tech Tour with six other partners: BPI France, Meta Group, EurA, BWCON, EBN, and IESE Business School.